{"filings":[{"id":508916,"accession_number":"0001193125-26-229714","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2026-05-19T12:07:26+00:00","items":["5.02"],"status":"ready","headline":"Artiva CFO departs; CEO assumes financial duties; Miralles becomes President","event_type":"leadership","confidence":"high","bullets":["CFO Thad Huston to leave May 22; receives $135k cash severance and 9 months COBRA; search begun.","CEO Fred Aslan becomes principal financial and accounting officer after stepping down as President.","Diego Miralles resigns from board, appointed President and Head of R&D; $600k salary, 45% bonus target.","Miralles awarded inducement equity: 232,500 options and 77,500 RSUs under 2025 Inducement Plan.","Board size reduced from 8 to 7; Miralles's consulting agreement ended May 17."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95723,"accession_number":"0001193125-26-214711","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Artiva Biotherapeutics raises ~$300M in common stock and pre-funded warrant offering","event_type":"other_material","confidence":"high","bullets":["Priced 23,871,526 shares at $11.52/share and 2,170,138 pre-funded warrants at $11.5199 each.","Gross proceeds ~$300M before underwriting discounts and expenses.","Offering managed by Jefferies, TD Securities, and Cantor Fitzgerald; closing expected May 11, 2026.","Pre-funded warrants exercisable immediately with 4.99% beneficial ownership cap; cap can be increased to 19.99%.","Company registered under S-3; shares and warrants listed on Nasdaq under ARTV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95722,"accession_number":"0001193125-26-213239","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M","event_type":"other_material","confidence":"high","bullets":["71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.","FDA aligned on single Phase 3 registrational trial for AlloNK in ~150 refractory RA patients; ACR50 at 6 months primary endpoint.","Safety: no CRS, ICANS, or AlloNK-related discontinuations; outpatient administration in community rheumatology clinics.","Q1 net loss $23.5M; cash $86.8M expected to fund operations into Q2 2027.","ATM sales suspended under Sales Agreement with Leerink; agreement remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108999,"accession_number":"0001193125-26-100131","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artiva reports FY2025 net loss of $83.9M; cash $108M into Q2 2027","event_type":"earnings","confidence":"high","bullets":["Net loss $83.9M vs $65.4M in 2024; R&D spend $69.5M (up 38% YoY); revenue zero.","Cash, equivalents and investments $108.0M as of Dec 31, 2025, expected to fund operations into Q2 2027.","AlloNK for refractory RA: initial clinical response data from ≥15 patients expected H1 2026; FDA Fast Track granted.","Planned FDA interaction in H1 2026 to discuss potential pivotal trial design for AlloNK in refractory RA.","Appointed Subhashis Banerjee, M.D. as CMO and Thad Huston as CFO; added two board members with immunology/commercial expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108998,"accession_number":"0001193125-26-067509","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Artiva Biotherapeutics appoints Thad Huston as CFO effective Feb 18, 2026","event_type":"leadership","confidence":"high","bullets":["Thad Huston appointed CFO, principal financial and accounting officer, effective Feb 18, 2026.","Salary $540,000; discretionary annual cash bonus target of 40% of base salary.","Inducement award of 220,000 RSUs vesting 25% Feb 15, 2027, then quarterly over three years.","Severance: 9 months base salary (non-CIC) or 12 months + full target bonus (CIC), plus COBRA and accelerated vesting.","Huston previously CFO/COO at Galapagos NV and held senior roles at Kite Pharma, LivaNova, and Johnson & Johnson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108997,"accession_number":"0001193125-26-059716","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Artiva Biotherapeutics appoints former AbbVie SVP Elaine Sorg as Class I director","event_type":"leadership","confidence":"high","bullets":["Elaine Sorg appointed as Class I director on Feb 18, 2026, term expiring at 2028 annual meeting.","No arrangements or transactions requiring disclosure under Item 404(a) were identified.","Compensation includes $40k annual cash retainer and initial option for 27,500 shares; one-third vests immediately, remainder monthly over two years.","Automatic annual option grants of 13,750 shares on each annual meeting date vest on one-year anniversary or next annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125459,"accession_number":"0001193125-25-317784","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Artiva Biotherapeutics exchanges underwater options for RSUs for CEO and COO","event_type":"other_material","confidence":"high","bullets":["CEO Fred Aslan surrendered 869,136 options (566,470 vested, 302,666 unvested) for equivalent RSUs with new vesting.","COO Jennifer Bush surrendered 84,877 options (60,372 vested, 24,506 unvested) for equivalent RSUs.","RSUs vest between Aug 2026 and Feb 2029; acceleration on termination without cause or resignation for good reason.","Purpose: retain employees and align interests with stockholders by replacing underwater options with current-value equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125458,"accession_number":"0001193125-25-275902","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Artiva reports AlloNK shows deep B-cell depletion in 32 autoimmune patients; FDA interaction planned 1H 2026","event_type":"other_material","confidence":"high","bullets":["32 patients dosed with AlloNK + anti-CD20 mAb as outpatients at community rheumatology sites; no CRS, ICANS or GvHD.","No Grade 3+ AlloNK-related TEAEs, no discontinuations; only one hospitalization (unrelated skin infection).","All 23 analyzed patients had undetectable peripheral CD19+ B-cells by Day 13; high-sensitivity assay confirms depletion.","B-cell depletion depth comparable to CD19-auto-CAR-T, greater than rituximab alone per published studies.","Plans to share initial RA response data from >15 patients and align with FDA on pivotal trial design in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125457,"accession_number":"0001193125-25-275867","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA","event_type":"earnings","confidence":"high","bullets":["Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.","Initial response data for >15 refractory RA patients expected 1H 2026; FDA discussions planned.","Cash, equivalents, investments $123M as of Sep 30, 2025; runway into Q2 2027.","Q3 R&D expense $17.6M, G&A $5.3M; net loss $21.5M vs $17.5M year ago.","CFO Neha Krishnamohan to step down end of Dec, advisory role; successor search underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142192,"accession_number":"0000950170-25-104028","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artiva reports Q2 net loss $21.3M; cash runway into Q2 2027; autoimmune trial progress","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.3M for Q2 2025 vs $17.8M in Q2 2024; R&D expenses $17.9M (up from $12.3M).","Cash, cash equivalents, and investments $142.4M as of June 30, 2025; funding into Q2 2027.","First patient treated in global Phase 2a basket trial of AlloNK + rituximab in refractory RA, Sjögren's, myositis, and scleroderma.","Over a dozen patients treated across autoimmune trials; initial safety/translational data by year-end 2025.","Lead indication for AlloNK to be disclosed by year-end 2025; initial clinical response data in 1H2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160190,"accession_number":"0000950170-25-089942","cik":1817241,"company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Artiva stockholders approve 1.2M share increase to 2024 equity plan, re-elect director Baker","event_type":"other_material","confidence":"high","bullets":["Amendment to 2024 Equity Incentive Plan approved, adding 1,214,580 shares to the share reserve; total now up to 7,001,185 shares.","Class I director Daniel Baker, Ph.D., re-elected with 18.9M votes for (98.9% of votes cast), 22,995 withheld.","KPMG LLP ratified as independent auditor for FY2025 with 20.8M votes for, 300 against, 2,272 abstain.","Plan also provides annual automatic increase of up to 5% of outstanding shares each January 1 through 2034."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}